Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

PL. Zinzani, M. Trněný, V. Ribrag, VR. Zilioli, J. Walewski, JH. Christensen, V. Delwail, G. Rodriguez, P. Venugopal, M. Coleman, C. Dartigeas, C. Patti, F. Pane, W. Jurczak, M. Taszner, S. Paneesha, F. Zheng, DJ. DeMarini, W. Jiang, A....

. 2023 ; 62 (-) : 102131. [pub] 20230810

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23015488

BACKGROUND: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19), the efficacy and safety of parsaclisib was evaluated in patients with R/R mantle cell lymphoma (MCL). METHODS: Patients ≥18 years old with pathologically confirmed R/R MCL and prior treatment with 1-3 systemic therapies, with (cohort 1) or without (cohort 2) previous Bruton kinase inhibitor (BTKi) treatment, received oral parsaclisib 20 mg once-daily (QD) for 8 weeks, then either parsaclisib 20 mg once-weekly (weekly dosing group [WG]) or parsaclisib 2.5 mg QD (daily dosing group [DG]). The primary endpoint was objective response rate (ORR). FINDINGS: At the primary analysis data cutoff on January 15, 2021, 53 patients in cohort 1 (BTKi-experienced) (WG, n = 12; DG: n = 41) and 108 patients in cohort 2 (BTKi-naive) (WG, n = 31; DG: n = 77) had received parsaclisib monotherapy. The BTKi-experienced cohort was closed after an interim analysis demonstrated limited clinical benefit. In the BTKi-naive cohort, the ORR (95% CI) for DG (dosing selected for further study) was 70.1% (58.6%-80.0%), with a complete response rate (95% CI) of 15.6% (8.3%-25.6%) and a median duration of response (95% CI) of 12.1 (9.0-not evaluable) months. Treatment-emergent adverse events (TEAEs) occurred among 90.7% (98/108) of all treated patients in the BTKi-naive cohort. Grade ≥3 TEAEs occurred among 62.0% (67/108) of patients, including diarrhoea (13.9%, 15/108) and neutropenia (8.3%, 9/108). Parsaclisib interruption, reduction, or discontinuation due to TEAEs occurred among 47.2% (51/108), 8.3% (9/108), and 25.0% (27/108) of patients, respectively. Fatal TEAEs were experienced by six patients and determined to be treatment-related in one patient. INTERPRETATION: Parsaclisib, a potent, highly selective, PI3Kδ inhibitor demonstrated meaningful clinical benefits and a manageable safety profile (25.0% discontinuation rate, low incidences of individually reported grade ≥3 or serious adverse events) in R/R MCL patients with no prior BTKi therapy. Limited clinical benefit was observed with parsaclisib monotherapy in patients who had previously received BTKi treatment. Future development of PI3K inhibitors for NHL will require further investigation of dose optimisation to improve safety and long-term survival. FUNDING: Incyte Corporation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015488
003      
CZ-PrNML
005      
20240313104529.0
007      
ta
008      
231010e20230810enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eclinm.2023.102131 $2 doi
035    __
$a (PubMed)37599908
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zinzani, Pier Luigi, $d 1959- $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy $7 xx0314852
245    10
$a Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study / $c PL. Zinzani, M. Trněný, V. Ribrag, VR. Zilioli, J. Walewski, JH. Christensen, V. Delwail, G. Rodriguez, P. Venugopal, M. Coleman, C. Dartigeas, C. Patti, F. Pane, W. Jurczak, M. Taszner, S. Paneesha, F. Zheng, DJ. DeMarini, W. Jiang, A. Gilmartin, A. Mehta
520    9_
$a BACKGROUND: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19), the efficacy and safety of parsaclisib was evaluated in patients with R/R mantle cell lymphoma (MCL). METHODS: Patients ≥18 years old with pathologically confirmed R/R MCL and prior treatment with 1-3 systemic therapies, with (cohort 1) or without (cohort 2) previous Bruton kinase inhibitor (BTKi) treatment, received oral parsaclisib 20 mg once-daily (QD) for 8 weeks, then either parsaclisib 20 mg once-weekly (weekly dosing group [WG]) or parsaclisib 2.5 mg QD (daily dosing group [DG]). The primary endpoint was objective response rate (ORR). FINDINGS: At the primary analysis data cutoff on January 15, 2021, 53 patients in cohort 1 (BTKi-experienced) (WG, n = 12; DG: n = 41) and 108 patients in cohort 2 (BTKi-naive) (WG, n = 31; DG: n = 77) had received parsaclisib monotherapy. The BTKi-experienced cohort was closed after an interim analysis demonstrated limited clinical benefit. In the BTKi-naive cohort, the ORR (95% CI) for DG (dosing selected for further study) was 70.1% (58.6%-80.0%), with a complete response rate (95% CI) of 15.6% (8.3%-25.6%) and a median duration of response (95% CI) of 12.1 (9.0-not evaluable) months. Treatment-emergent adverse events (TEAEs) occurred among 90.7% (98/108) of all treated patients in the BTKi-naive cohort. Grade ≥3 TEAEs occurred among 62.0% (67/108) of patients, including diarrhoea (13.9%, 15/108) and neutropenia (8.3%, 9/108). Parsaclisib interruption, reduction, or discontinuation due to TEAEs occurred among 47.2% (51/108), 8.3% (9/108), and 25.0% (27/108) of patients, respectively. Fatal TEAEs were experienced by six patients and determined to be treatment-related in one patient. INTERPRETATION: Parsaclisib, a potent, highly selective, PI3Kδ inhibitor demonstrated meaningful clinical benefits and a manageable safety profile (25.0% discontinuation rate, low incidences of individually reported grade ≥3 or serious adverse events) in R/R MCL patients with no prior BTKi therapy. Limited clinical benefit was observed with parsaclisib monotherapy in patients who had previously received BTKi treatment. Future development of PI3K inhibitors for NHL will require further investigation of dose optimisation to improve safety and long-term survival. FUNDING: Incyte Corporation.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Trněný, Marek $u Charles University, General Hospital, Prague, Czech Republic
700    1_
$a Ribrag, Vincent $u Institut Gustave Roussy, Villejuif, France
700    1_
$a Zilioli, Vittorio Ruggero $u ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
700    1_
$a Walewski, Jan $u Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Christensen, Jacob Haaber $u Department of Hematology, Odense University Hospital, Denmark
700    1_
$a Delwail, Vincent $u CHU Poitiers, Poitiers, France
700    1_
$a Rodriguez, Guillermo $u Hospital Universitario Virgen del Rocío, Seville, Spain
700    1_
$a Venugopal, Parameswaran $u Rush University, Chicago, IL, USA
700    1_
$a Coleman, Morton $u Clinical Research Alliance/Cornell Medicine, New York, NY, USA
700    1_
$a Dartigeas, Caroline $u Hématologie et Thérapie Cellulaire, CHRU de Tours, Tours, France
700    1_
$a Patti, Caterina $u Department of Oncohematology Unit, Azienda Ospedali Riuniti Villa Sofia Cervello, Palmero, Italy
700    1_
$a Pane, Fabrizio $u University of Naples Federico II, Naples, Italy
700    1_
$a Jurczak, Wojciech $u Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
700    1_
$a Taszner, Michal $u Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
700    1_
$a Paneesha, Shankara $u Birmingham Heartlands Hospital, Birmingham, UK
700    1_
$a Zheng, Fred $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a DeMarini, Douglas J $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Jiang, Wei $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Gilmartin, Aidan $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Mehta, Amitkumar $u UAB School of Medicine, Birmingham, AL, USA
773    0_
$w MED00200566 $t EClinicalMedicine $x 2589-5370 $g Roč. 62 (20230810), s. 102131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37599908 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20240313104525 $b ABA008
999    __
$a ok $b bmc $g 1997158 $s 1201850
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 62 $c - $d 102131 $e 20230810 $i 2589-5370 $m EClinicalMedicine $n EClinicalMedicine $x MED00200566
LZP    __
$a Pubmed-20231010

Find record

Citation metrics

Archiving options